Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs

Abstract

Background:Survivin, a member of the inhibitor of apoptosis protein family, is an attractive target for cancer therapy. We have now investigated the effects of the combination of YM155, a novel small-molecule inhibitor of survivin expression, and platinum compounds (cisplatin and carboplatin) on human non-small cell lung cancer (NSCLC) cell lines.Methods… (More)
DOI: 10.1038/sj.bjc.6605713

Topics

3 Figures and Tables

Slides referencing similar topics